Largest Milestone Payment Secured: Biokin, a Rising Chinese Pharmaceutical MNC

About this update from Sichuan Biokin Pharmaceutical Co., Ltd. Class A

[{"type":"text","content":"BEIJING, Oct. 22, 2025 /PRNewswire/ -- In October 2025, a partnership between Biokin—a rising star in China's innovative pharmaceutical sector—and global pharmaceutical leader BMS triggered a $250 million milestone payment. This is believed to be the largest antibody-drug conjugate (ADC) milestone payment among hundreds of out-licensing deals involving Chinese innovative drugs. Notably, the overall transaction had previously set a record for the total value of a single-drug asset license in China.","length":506,"tagName":"p"},{"type":"image","alt":"iza-bren, a potential first-in-class ADC comprised of an EGFR x HER3 bispecific antibody conjugated (PRNewsfoto/Biokin)","displaySize":"","headline":null,"caption":"iza-bren, a potential first-in-class ADC comprised of an EGFR x HER3 bispecific antibody conjugated (PRNewsfoto/Biokin)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":225,"url":"https://media.zenfs.com/en/prnewswire.com/8ca83854dfdbcfaae4e470b67cd78915"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WZstv_ykBGzVJAfiFaunmA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM5NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/8ca83854dfdbcfaae4e470b67cd78915","width":400,"height":225}},"href":"https://mma.prnewswire.com/media/2802851/1202900558.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"In recent years, China's dynamic pharmaceutical ecosystem has rapidly emerged as one of the world's leading sources of novel drug molecules. Such collaborations, however, often come with uncertainties in both China and the U.S. Following the $800 million upfront payment received in early 2024, Biokin's partnership with BMS has advanced smoothly once again. This progress has prompted skeptics to recognize iza-bren's blockbuster potential.","length":457,"tagName":"p"},{"type":"text","content":"The momentum behind the collaboration stems from the continued validation of iza-bren's efficacy. At the 2025 World Congress on Lung Cancer (WCLC), after Dr. Fang Wenfeng presented domestic clinical data, a physician from the prestigious MD Anderson Cancer Center in the U.S. approached him, expressing hope the drug would launch in the U.S. as soon as possible.","length":366,"tagName":"p"},{"type":"text","content":"Such a conversation would have been unimaginable in the pas...

More updates from Sichuan Biokin Pharmaceutical Co., Ltd. Class A